COVID-19 Funding Snapshot for Pharma Developers/Manufacturers Views as of August 7, 2020 Presentations August 21, 2020 Lain Anderson Cassie Guo Adam Nover
Contributing authors: Tony Stripling, Associate Consultant Sean Saunders, Life Sciences Speciaist Jennifer Henry, Associate Consultant Patrick Marquet, Associate Related Practice Life Sciences & Pharma The COVID-19 pharmaceutical funding landscape is evolving at a rapid pace, yet several initial insights have emerged 01262022160100
Published Articles Biotech and Pharmaceuticals EU Pharmaceutical Legislation Revisions: What Are the Implications for Biopharma? December 20, 2023
Executive Insights Business Services Benefits of the 4-Day Week: The Jury Is Still Out October 31, 2023
Executive Insights Organization & Performance Disruptive Trends in Corporate Transformation: Converting Ideas Into Action August 23, 2023
Executive Insights Life Sciences & Pharma EUnetHTA 21 — Transition to EU-wide HTAs: Implications for Pharma July 31, 2023